Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To compare the efficacy and safety of urapidil (i/v solution 5 mg/ml in 5 and 10 ml ampoules) and enalaprilat (i/v solution 1.25 mg/ml in 1 ml ampoules) in the treatment of complicated hypertensive crises in patients with arterial hypertension, 1-3 degrees. Material and methods. Patients with complicated hypertensive crisis (n=70) were included into the comparative randomized study. Patients were randomized for treatment with urapidil (the initial dose 12.5 mg; if there was no effect after 15 minutes it was possible to re-infused urapidil 12.5 mg) or enalaprilat (the initial dose 1.25 mg). The frequency of target blood pressure (BP) achievement, BP and heart rate dynamics, as well as safety of treatment were evaluated in groups during 6 hours. Results. The frequency of target BP achievement in the urapidil treatment group was higher than this in enalaprilat group (96.7 vs 73.3%; p<0.001), for the first hour systolic BP (SBP) in the urapidil group reduced from 210.5±13.6 to 157.8±8.3 mmHg (p<0.05), and diastolic BP (DBP) - from 115.7±8.5 to 86.9±9.1 mmHg (p<0.05). In the enalaprilat group in the first hour SBP reduced from 208.1 to 182.5 mmHg (p<0.05), DBP — from 114.8 to 95.0 mmHg (p<0.05). During next 6 hours the urapidil group demonstrated longer lasting antihypertensive effect in comparison with enalaprilat. Both drugs did not have a significant effect on heart rate and showed no significant adverse events. In next 72 hours no one acute vascular event was registered in the patients of both groups. Conclusion. Urapidil is an effective and safe drug for arresting of complicated hypertensive crises. Its efficacy is not inferior to this of enalaprilat.

About the Authors

G. P. Arutyunov
The Russian National Research Medical University named after N.I. Pirogov
Russian Federation

L. G. Oganezova
The Russian National Research Medical University named after N.I. Pirogov
Russian Federation


1. Oganov R.G. The development of preventive cardiology in Russia. Kardiovaskulyarnaya terapiya i profilaktika 2004; 3(3) part 1: 10–14. Russian (Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика 2004; 3(3) ч.1: 10–14).

2. Varonj, Marik P.E. The diagnosis and management of hypertensive crises. Chest 2000; 118: 214-27.

3. Vaughan C.J., Delanty N. Hypertensive emergencies. Lancet 2000; 356:411-7.

4. Eliott W.J. Clinical features and management of selected hypertensive emergrncies. J Clin Hypertens 2004; 6:587-92.

5. Aggarwal M., Khan I.A. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin 2006; 24:135-46.

6. National guidelines for diagnosis and treatment of hypertension. The Assembly of Experts SCRF, RM-SAH. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7 (6) suppl 2: 1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Совет экспертов ВНОК, РМО-АГ. Кардиоваскулярная терапия и профилактика 2008; 7 (6) приложение 2: 1-32).

7. Rhoney D., Peacock W.F. Intravenous therapy for hypertensive emergencies, part 1. Am J Health-Syst Pharm 2009; 66:1343-52

8. Bales A. Hypertensive crisis. How to tell if it’s an emergency or an urgency. Postgrad Med 1999; 105: 119-126, 130.

9. Zampaglione B., Pascale C., Marchisio M., Santoro A. The use of lacidipine in the management of hypertensive crises: a comparative study with nifedipine. J Cardiovasc Pharmacol 1994; 23 (Suppl 5): S116-118.

10. Gifford R. Management of hypertensive crises. JAMA 1991; 226: 829-835.

11. Finnerty FA. Hypertensive encephalopathy. Am J Med 1972; 52: 672-78.

12. Vertkin A.L., Gorodetskiy V.V., Topolyanskiy A.V. et al. Prehospital and other assistance to the sudden increase in blood pressure and hypertensive crisis. Russkiy meditsinskiy zhurnal 2001; 9(20): 863-867. Russian (Верткин А.Л., Городецкий В.В., Тополянский А.В. и др. Догоспитальная помощь при внезапном повышении АД и гипертоническом кризе. Русский медицинский журнал 2001; 9(20): 863-867).

13. Лукьянов М.М., Голиков А.П. Гипертонические кризы: основные положения диагностики, лечения и профилактики. Consilium-medicum 2010; 3:37-40.

14. Stoschitzky K., Stoschitzky G., Wonisch M., Brussee H. Differential effects of urapidil and doxazosin on heart rate. Eur J Clin Pharmacol 2007;63(3):259-62.

15. Hirschl M.M., Seidler D., Zeiner A. et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med 1993;11(6):653-6.

16. Hirschl M.M., Binder M., Bur A. et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensiv emergencies. Intensive Care Med 1997;23(8):885-8.

For citation:

Arutyunov G.P., Oganezova L.G. ARRESTING OF COMPLICATED HYPERTENSIVE CRISES IN THE PHYSICIAN’S PRACTICE: URAPIDIL VALUE AND STUDY RESULTS. Rational Pharmacotherapy in Cardiology. 2011;7(5):549-554. (In Russ.)

Views: 782

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)